Prognostic significance of TIMP-1 in non-small cell lung cancer

Anticancer Research

Volumn 31, Issue 11, 2011, Pages 4031-4038

  Pesta, Martin ^a   Kulda, Vlastimil ^a   Radek, Kucera ^a   Pesek, Milos ^b   Vrzalova, Jindra ^a   Liska, Vaclav ^b   Pecen, Ladislav ^a   Treska, Vladislav ^b   Safranek, Jarmil ^b   Prazakova, Marketa ^a   Vycital, Ondrej ^b   Bruha, Jan ^b   Holubec, Lubos ^b   Topolcan, Ondrej ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Blood plasma; DFI; mRNA; Non small cell lung cancer; Survival; TIMP1

Indexed keywords

MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE INTERVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 83055174788     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. D'Addario Gand Felip E: ESMO Guidelines Working Group: Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(suppl 4): 68-70, 2009.
2. Gridelli C, Maione P, Rossi A, Ferrara ML, Castaldo V, Palazzolo G and Mazzeo N: Treatment of advanced non-small cell lung cancer in the elderly. Lung Cancer 66(3): 282-286, 2009.
3. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C and Topolcan O: Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43(9): 1348-1360, 2007. (Pubitemid 46874070)
4. Birgisson H, Nielsen HJ, Christensen IJ, Glimelius B and Brünner N: Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study. Eur J Cancer 46(18): 3323-3331, 2010.
5. Nielsen HJ, Brünner N, Frederiksen C, Lomholt AF, King D, Jørgensen LN, Olsen J, Rahr HB, Thygesen K, Hoyer U, Laurberg S, Christensen IJ: Danish-Australian Endoscopy Study Group On Colorectal Cancer Detection; Danish Colorectal Cancer Cooperative Group: Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): a novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection. Scand J Gastroenterol 43(2): 242-248, 2008. (Pubitemid 351161531)
6. Inagaki D, Oshima T, Yoshihara K, Tamura S, Kanazawa A, Yamada T, Yamamoto N, Sato T, Shiozawa M, Morinaga S, Akaike M, Fujii S, Numata K, Kunisaki C, Rino Y, Tanaka K, Masuda M and Imada T: Overexpression of tissue inhibitor of metalloproteinase-1 gene correlates with poor outcomes in colorectal cancer. Anticancer Res 30(10): 4127-4130, 2010.
7. Jensen SA, Vainer B, Bartels A, Brünner N and Sørensen JB: Expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) by colorectal cancer cells and adjacent stroma cells-associations with histopathology and patients outcome. Eur J Cancer 46(18): 3233-3242, 2010.
8. Waas ET, Hendriks T, Lomme RM and Wobbes T: Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metallo-proteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 48(4): 700-710, 2005. (Pubitemid 40880716)
9. Talvensaari-Mattila A and Turpeenniemi-Hujanen T: High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma. Breast Cancer Res Treat 89(1): 29-34, 2005. (Pubitemid 40232997)
10. Würtz SØ, Møller S, Mouridsen H, Hertel PB, Friis E and Brünner N: Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study. Mol Cell Proteomics 7(2): 424-430, 2008.
11. Honkavuori M, Talvensaari-Mattila A, Puistola U, Turpeenniemi-Hujanen T and Santala M: High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma. Anticancer Res 28(5A): 2715-2719, 2008.
12. Gouyer V, Conti M, Devos P, Zerimech F, Copin MC, Créme E, Wurtz A, Porte H and Huet G: Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with non-small cell lung carcinoma who undergo resection with curative intent. Cancer 103(8): 1676-1684, 2005. (Pubitemid 40490029)
13. Suemitsu R, Yoshino I, Tomiyasu M, Fukuyama S, Okamoto T and Maehara Y: Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer. Surg Today 34(11): 896-901, 2004. (Pubitemid 40326465)
14. Dubinett SM, Elashoff D and Meyerson M: Assessing prognosis in non-small cell lung cancer: Avenues to a more complete picture? J Clin Oncol 22(16): 3209-3211, 2004. (Pubitemid 41103673)
15. Simi L, Andreani M, Davini F, Janni A, Pazzagli M, Serio M and Orlando C: Simultaneous measurement of MMP9 and TIMP1 mRNA in human non-small cell lung cancers by multiplex real time RT-PCR. Lung Cancer 45(2): 171-179, 2004. (Pubitemid 38891479)
16. Brew K, Dinakarpandian D and Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477(1-2): 267-283, 2000. (Pubitemid 30119906)
17. Stetler-Stevenson WG: Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 1(27): re6, 2008.
18. Brew K and Nagase H: The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 1803(1): 55-71, 2010.
19. Hornebeck W, Lambert E, Petitfrère E and Bernard P: Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression. Biochimie 87(3-4): 377-383, 2005. (Pubitemid 40387617)
20. Hayakawa T, Yamashita K, Ohuchi E and Shinagawa A: Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 107(Pt 9): 2373-2379, 1994. (Pubitemid 24292486)
21. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E and Iwata K: Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298(1): 29-32, 1992.
22. Corcoran ML and Stetler-Stevenson WG: Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. J Biol Chem 270(22): 13453-13459, 1995.
23. Yamashita K, Suzuki M, Iwata H, Koike T, Hamaguchi M, Shinagawa A, Noguchi T and Hayakawa T: Tyrosine phosphorylation is crucial for growth signaling by tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) FEBS Lett 396(1): 103-107, 1996. (Pubitemid 26360290)
24. Wang T, Yamashita K, Iwata K and Hayakawa T: Both tissue inhibitors of metalloproteinases-1 (TIMP-1) and TIMP-2 activate Ras but through different pathways. Biochem Biophys Res Commun 296(1): 201-205, 2002. (Pubitemid 35002079)
25. Guedez L, Mansoor A, Birkedal-Hansen B, Lim MS, Fukushima P, Venzon D, Stetler-Stevenson WG and Stetler-Stevenson M: Tissue inhibitor of metalloproteinases 1 regulation of interleukin-10 in B-cell differentiation and lymphomagenesis. Blood 97(6): 1796-1802, 2001. (Pubitemid 32217248)
26. Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, Roshy S, Sloane BF, Fridman R and Kim HR: Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 65(3): 898-906, 2005. (Pubitemid 40216449)
27. Fata JE, Leco KJ, Moorehead RA, Martin DC and Khokha R: TIMP-1 is important for epithelial proliferation and branching morphogenesis during mouse mammary development. Dev Biol 211(2): 238-254, 1999. (Pubitemid 29343279)
28. Taube ME, Liu XW, Fridman R and Kim HR: TIMP-1 regulation of cell cycle in human breast epithelial cells via stabilization of p27(KIP1) protein. Oncogene 25(21): 3041-3048, 2006. (Pubitemid 43780468)
29. Pesta M, Holubec L Jr., Topolcan O, Cerna M, Rupert K, Holubec LS, Treska V, Kormunda S, Elgrova L, Finek J and Cerny R: Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples. Anticancer Res 25(5): 3387-3391, 2005. (Pubitemid 41105215)
30. de Mingo M, Morán A, Sánchez-Pernaute A, Iniesta P, Díez-Valladares L, Pérez-Aguirre E, de Juan C, García-Aranda C, Díaz-López A, García-Botella A, Martín-Antona E, Benito M, Torres A and Balibrea JL: Expression of MMP-9 and TIMP-1 as prognostic markers in gastric carcinoma. Hepatogastroenterology 54(73): 315-319, 2007. (Pubitemid 46511697)
31. Morán A, Iniesta P, García-Aranda C, De Juan C, Díaz-López A, Sánchez-Pernaute A, Torres AJ, Díaz-Rubio E, Balibrea JL and Benito M: Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer. Oncol Rep 13(1): 115-120, 2005.
32. Safranek J, Pesta M, Holubec L, Kulda V, Dreslerova J, Vrzalova J, Topolcan O, Pesek M, Finek J and Treska V: Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer Res 29(7): 2513-2517, 2009.
33. Aljada IS, Ramnath N, Donohue K, Harvey S, Brooks JJ, Wiseman SM, Khoury T, Loewen G, Slocum HK, Anderson TM, Bepler G and Tan D: Up-regulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small cell lung cancer. J Clin Oncol 22(16): 3218-3229, 2004. (Pubitemid 41103676)
34. Iniesta P, Morán A, De Juan C, Gómez A, Hernando F, García-Aranda C, Frías C, Díaz-López A, Rodríguez-Jiménez FJ, Balibrea JL and Benito M: Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncol Rep 17(1): 217-223, 2007.
35. Fong KM, Kida Y, Zimmerman PV and Smith PJ: TIMP1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res 2(8): 1369-1372, 1996. (Pubitemid 26299436)
36. Ylisirniö S, Höyhtyä M and Turpeenniemi-Hujanen T: Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer - TIMP-1 as a prognostic marker. Anticancer Res 20(2B): 1311-1316, 2000. (Pubitemid 30240720)
37. Suemitsu R, Yoshino I, Tomiyasu M, Fukuyama S, Okamoto T and Maehara Y: Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer. Surg Today 34(11): 896-901, 2004. (Pubitemid 40326465)